Inscripta, a genome editing firm, completed the acquisition of Infinome Biosciences, a biotechnology firm. Financial terms were not disclosed. "Tackling the unprecedented opportunity to improve global health and sustainability through biomanufacturing requires a strong combination of talent, experience, technology, and commercial assets. Infinome and Sestina Bio allow us to advance our strategy and complement our technological innovation and capabilities needed for creating the next generation of biobased manufacturing products and processes," Sri Kosaraju, Inscripta CEO.